Physician profile
Melissa J Murray
NPI 1689651168
$15,280.53
in general payments reported to CMS, 2019-2025
54 companies · $2,222 in 2025
The $2,222 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $1,408 · 2021: $2,447 · 2022: $2,105 · 2023: $2,754 · 2024: $2,435 · 2025: $2,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,410.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,828.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,104.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $984.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $926.33 | 2019-2025 | |
| Novo Nordisk INC | $923.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $833.88 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $686.14 | 2019-2025 | Xifaxan |
| Amgen INC. | $613.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $504.17 | 2019-2025 | Trintellix |
| Allergan, INC. | $447.31 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $380.98 | 2019-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $358.60 | 2022-2025 | Caplyta |
| Abbott Laboratories | $319.10 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.36 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $214.72 | 2023-2025 | Auvelity, Symbravo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.